Balancing Novelty, Safety, and Availability: The Trifecta of Outcomes in Pharmaceutical Supply Chains
2024-05
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Balancing Novelty, Safety, and Availability: The Trifecta of Outcomes in Pharmaceutical Supply Chains
Authors
Published Date
2024-05
Publisher
Type
Thesis or Dissertation
Abstract
Global pharmaceutical supply chains have garnered unprecedented attention, particularly in the wake of the COVID-19 pandemic. Despite their importance, pharmaceutical supply chains are plagued by numerous challenges such as stagnating innovation, increasing drug shortages, and drugs with compromised quality reaching patients. While efforts to resolve these issues hold potential, their implementation often inadvertently leads to unintended consequences. Such tradeoffs, i.e., solutions to one problem unintentionally creating another problem, present a challenge for pharmaceutical supply chains. Despite the central role of tradeoffs in Operations Management research, their understanding within the pharmaceutical supply chain context remains limited. This dissertation serves as an exploration of the tradeoffs within pharmaceutical supply chains. Titled “Balancing Novelty, Safety, and Availability: The Trifecta of Outcomes in Pharmaceutical Supply Chains,” it delves into fundamental questions, such as What is the nature and the extent of these tradeoffs? and, How can supply chain stakeholders mitigate their impact? By concentrating on three pivotal outcomes – novelty, safety, and availability – I examine how efforts meant to improve one of the three outcomes could unintendedly impact other outcomes. Chapter 1 serves as a motivation for the topic and provides a brief overview of the ensuing dissertation essays. In Chapter 2, I show how enhanced transparency in clinical trials, intended to enhance patient safety, may hinder drug novelty. In Chapter 3, I examine the adverse effects of the expedited approval process, aimed at improving the availability of novel drugs, on drug safety. In Chapter 4, I delve into the impact of quality failures on drug availability, discerning when failures help or hurt availability. Chapter 5 concludes with insights the dissertation entails for Operations Management scholars, managers, and policymakers. These dissertation essays aim to evaluate the inherent tradeoffs within the pharmaceutical industry and propose interventions for mutually enhancing operational outcomes. While the overarching goal is to improve outcomes within the pharmaceutical supply chain, the insights from this work also inform a wider array of Operations Management questions beyond the confines of the pharmaceutical industry.
Description
University of Minnesota Ph.D. dissertation. May 2024. Major: Business Administration. Advisor: Rachna Shah. 1 computer file (PDF); xii, 166 pages.
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Tyagi, Hanu. (2024). Balancing Novelty, Safety, and Availability: The Trifecta of Outcomes in Pharmaceutical Supply Chains. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/264369.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.